Table 2 Efficacy data on regorafenib therapy
Variable | Total (n = 93) |
|---|---|
Response by mRECIST, n (%) | |
Complete response | 2 (2.2) |
Partial response | 11 (11.8) |
Stable disease | 45 (48.4) |
Progressive disease | 35 (37.6) |
Objective response rate, n (%) | 13 (14.0) |
Disease control rate, n (%) | 58 (62.4%) |
Time of first-line drug treatment, median months (95%CI) | 6.9 (6.0–8.8) |
Time of regorafenib treatment, median months (95%CI) | 9.2 (5.9–12.0) |
Time of follow up, median months (95%CI) | 14.5 (13.0–16.9) |
Overall survival, median months (95%CI) | 15.9 (11.7/20.1) |
Overall survival from first-line drug treatment, median months (95%CI) | 26.3 (20.3/32.3) |
Time to progression, median months (95%CI) | 5.0 (4.1/5.9) |